RxDoctor Payments Data

Delaney French, MD

Family Medicine · Palestine, TXNPI 1861405417

Payments from drug & device makers

$10,538in general payments, 2019–2025

Across 577 payments — averaging $18.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Amgen$1K
  • Boehringer Ingelheim$837
  • Lilly USA, LLC$795
  • Novo Nordisk$700
  • Supernus Pharmaceuticals, Inc.$684
  • plus $5K from 37 others

What the payments were for

  • Food & beverage$10,43599%
  • Education$1031%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,538 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$141,627
Medicare patients
245
Services billed
7,939

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide129$137,932
OzempicSemaglutide103$99,959
FarxigaDapagliflozin Propanediol85$74,047
JardianceEmpagliflozin55$48,306
EliquisApixaban56$45,290
XareltoRivaroxaban43$34,103
Repatha SureclickEvolocumab33$22,579
MyrbetriqMirabegron14$10,305
SymbicortBudesonide/Formoterol Fumarate31$8,693
Breo ElliptaFluticasone/Vilanterol13$7,362
Mirabegron ErMirabegron12$5,500
PremarinEstrogens, Conjugated12$3,520
Levothyroxine Sodium374$3,492
Famotidine135$2,462
Omeprazole166$2,370

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$795$137,932129 claims
Novo NordiskOzempic$700$99,959103 claims
AstraZenecaFarxiga, Symbicort$1,703$82,740116 claims
PfizerEliquis, Premarin$205$48,81068 claims
Boehringer IngelheimJardiance$837$48,30655 claims
Johnson & JohnsonXarelto$583$34,10343 claims
Astellas Pharma US IncMyrbetriq$173$10,30514 claims
GSKBreo Ellipta$509$7,36213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Palestine

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →